{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:19:20Z","timestamp":1790263160028,"version":"4.1.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T00:00:00Z","timestamp":1514246400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AI117943"],"award-info":[{"award-number":["P30 AI117943"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001422"],"award-info":[{"award-number":["UL1TR001422"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,17]]},"DOI":"10.1093\/cid\/cix1131","type":"journal-article","created":{"date-parts":[[2017,12,23]],"date-time":"2017-12-23T00:43:43Z","timestamp":1513989823000},"page":"1794-1797","source":"Crossref","is-referenced-by-count":82,"title":["Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial"],"prefix":"10.1093","volume":"66","author":[{"given":"Babafemi O","family":"Taiwo","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C","family":"Marconi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiba","family":"Berzins","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlee B","family":"Moser","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amesika N","family":"Nyaku","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Rutgers University, Newark, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J","family":"Fichtenbaum","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance A","family":"Benson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Wilkin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"Koletar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Colasanti","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P","family":"Acosta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Z","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E","family":"Sax","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,12,21]]},"reference":[{"key":"key\n\t\t\t\t20180626050739_CIT0001","unstructured":"Libre JM , HungCC, BrinsonC, et al Phase III SWORD 1&2: switch to DTG+RPV maintains virologic suppression through 48 wks. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI);13\u201316 February 2017, Seattle. Abstract 44LB"},{"key":"key\n\t\t\t\t20180626050739_CIT0002","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180626050739_CIT0003","first-page":"1163","article-title":"Treatment simplification to atazanavir\/ritonavir+lamivudine versus maintenance of atazanavir\/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)","volume":"72","author":"Di Giambenedetto","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180626050739_CIT0004","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(15)00096-1","article-title":"Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial","volume":"15","author":"Arribas","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180626050739_CIT0005","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","article-title":"Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 trial","volume":"65","author":"Pulido","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180626050739_CIT0006","first-page":"642","article-title":"2014 Update of the drug resistance mutations in HIV-1","volume":"22","author":"Wensing","year":"2014","journal-title":"Top Antivir Med"},{"key":"key\n\t\t\t\t20180626050739_CIT0007","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jchromb.2013.11.054","article-title":"A sensitive HPLC-MS\/MS method for the determination of dolutegravir in human plasma","volume":"945\u2013946","author":"Bennetto-Hood","year":"2014","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"key\n\t\t\t\t20180626050739_CIT0008","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/QAD.0b013e32834a1dd9","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults","volume":"25","author":"Min","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180626050739_CIT0009","unstructured":"Joly V , BuretC, LandmanR, et al Promising results of dolutegravir + lamivudine maintenance in ANRS 167 LAMIDOL trial. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); 13\u201316 February 2017, Seattle. Abstract 458"},{"key":"key\n\t\t\t\t20180626050739_CIT0010","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/civ981","article-title":"The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States","volume":"62","author":"Girouard","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180626050739_CIT0011","unstructured":"Taiwo BO , ZhengL, NyakuAN, et al ACTG A5353: a pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies\/mL. Presented at: Conference of the International AIDS Society (IAS); 23\u201326 July 2017, Paris, France. Abstract MOAB0103."},{"key":"key\n\t\t\t\t20180626050739_CIT0012","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/infdis\/jir518","article-title":"Factors associated with virological failure in HIV-1-infected patients receiving darunavir\/ritonavir monotherapy","volume":"204","author":"Lambert-Niclot","year":"2011","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/66\/11\/1794\/25084312\/cix1131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T11:34:10Z","timestamp":1570534450000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/66\/11\/1794\/4775007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,21]]},"references-count":12,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,12,21]]},"published-print":{"date-parts":[[2018,5,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix1131","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6,1]]},"published":{"date-parts":[[2017,12,21]]}}}